Liquid Biopsy-Directed Treatment Improves Advanced NSCLC Overall Survival
Advanced NSCLC patients who receive targeted treatment based on circulating tumour or tissue-detected DNA alterations have better overall survival than those who do not
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Advanced NSCLC patients who receive targeted treatment based on circulating tumour or tissue-detected DNA alterations have better overall survival than those who do not
Preliminary results point to datopotamab deruxtecan tolerability and potential efficacy against advanced triple-negative breast cancer
Adding alisertib to paclitaxel chemotherapy may improve progression-free survival for patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer
Breast cancer patients with distant lymph node metastases show survival outcomes similar to women with locoregional disease
Comprehensive next-generation sequencing can identify the primary tumour site in carcinoma of unknown origin, while patients with metastatic solid tumours may benefit from germline testing
Advanced urothelial cancer patients who have received a PD-1 or PD-L1 inhibitor and are unable to have cisplatin may benefit from enfortumab vedotin therapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.